FDA Panel Okays Keytruda’s Hepatocellular Carcinoma Indication, But Splits On Opdivo

 
• By Brenda Sandburg

In 5-4 vote, US FDA advisory committee recommends withdrawal of Opdivo’s accelerated approval for second-line treatment of HCC while unanimously supporting the indication in Keytruda pending outcome of ongoing studies.

Opposite results
FDA advisory panel reaches opposite conclusions on Keytruda, Opdivo HCC indication • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers